A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Tanya Barauskas DorffLisa G HorvathKaren A AutioAlice Bernard-TessierMatthew B RettigJean-Pascal H MachielsMehmet Asim BilenMartijn Paul LolkemaNabil AdraSylvie RotteyRichard GreilNobuaki MatsubaraDaniel Shao-Weng TanAlvin S C WongHiroji UemuraCharlotte LemechJohannes MeranYoufei YuMukul MinochaMason McCombHweixian Leong PennyVinita GuptaXuguang HuGabor JuridaHosein Kouros-MehrMargit M Janát-AmsburyTobias EggertBen TranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.